Lin S C
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi. 1986 Aug;19(3):183-8.
Beta-2 microglobulin (beta-MG) is a low molecular weight protein of 100 amino-acids. It is the light chain of HLA-A, -B or -C antigens which on the surface of nearly all nucleated cells. Clinically, the serum levels of beta-MG are increased in patients with renal failure, immune disorders, and various malignant diseases. In this study, the serum levels of beta-MG were measured clinically for a total of 114 cases. Diverse conditions were ensured by biopsy except for 10 control cases, and the following eight groups were diversified: (1) control group, 10 cases; (2) oral carcinoma, 36 cases; (3) mixed tumor, 7 cases; (4) pyogenic granuloma, 12 cases; (5) leukoplakia, 18 cases; (6) mucocele, 15 cases; (7) ameloblastoma, 7 cases; (8) fibroma, 9 cases. The serum levels of beta-MG in oral cancer and leukoplakia patients were found to be significantly higher compared with that of the control group and patients with benign oral tumors. Further study to unravel the correlations between the clinical stages, the treatment of oral cancer, and beta-MG is now in progress.
β2微球蛋白（β-MG）是一种由100个氨基酸组成的低分子量蛋白质。它是几乎所有有核细胞表面HLA-A、-B或-C抗原的轻链。临床上，肾衰竭、免疫紊乱和各种恶性疾病患者的血清β-MG水平会升高。在本研究中，对总共114例患者进行了血清β-MG水平的临床检测。除10例对照病例外，通过活检确保了多种病情，分为以下八组：（1）对照组，10例；（2）口腔癌，36例；（3）混合瘤，7例；（4）化脓性肉芽肿，12例；（5）白斑，18例；（6）黏液囊肿，15例；（7）成釉细胞瘤，7例；（8）纤维瘤，9例。发现口腔癌和白斑患者的血清β-MG水平明显高于对照组和良性口腔肿瘤患者。目前正在进行进一步研究，以阐明口腔癌的临床分期、治疗与β-MG之间的相关性。
